Institute for Clinical and Economic Review, Boston, MA.
Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago.
J Manag Care Spec Pharm. 2021 May;27(5):667-673. doi: 10.18553/jmcp.2021.27.5.667.
Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from AbbVie, Aetna, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Agboola, Rind, Herron-Smith, and Pearson are employed by ICER. Walton and Quach, through the University of Illinois at Chicago, received funding from ICER for development of the economic model described in this report.
本摘要的资助方为阿诺德基金会、加州医疗基金会、多纳休基金会、哈佛朝圣者健康保健、凯撒基金会健康计划,用以支持临床与经济评论学会(ICER)的工作。ICER 是一家独立的评估医疗干预措施价值的机构。ICER 的年度政策峰会由 AbbVie、Aetna、美国健康保险计划协会、Anthem、Alnylam、阿斯利康、Biogen、加州蓝盾、勃林格殷格翰、Cambia 健康服务、CVS、Editas、Evolve 药房、Express Scripts、基因泰克/罗氏、葛兰素史克、哈佛朝圣者、医疗服务公司、HealthFirst、Health Partners、Humana、强生(杨森)、凯撒永久、利奥制药、美纳里克斯、默克、诺华、国家药品理事会、辉瑞、Premera、Prime 治疗学、再生元、赛诺菲、Spark Therapeutics、uniQure 和联合健康。Agboola、Rind、Herron-Smith 和 Pearson 在 ICER 任职。Walton 和 Quach 通过芝加哥大学获得了 ICER 的资金,用以开发本报告中所描述的经济模型。